[Breast cancer : individualized risk assessment for tailor-made screening]. / Cancer du sein : évaluation individualisée du risque en vue d'un dépistage sur mesure.

Breast cancer is the leading cause of neoplastic death in women around the world. In the era of personalized medicine, legitimately awaited by our patients, the future of breast cancer screening will depend on an individual-based risk assessment, making it possible to better adapt the age of onset, frequency and the type of examinations useful for this screening. This article reviews the three broad categories of highest risk factors available to establish a risk score appropriate for each patient.

Le cancer du sein est la première cause de mortalité par néoplasie chez la femme de par le monde. À l'ère d'une médecine personnalisée, légitimement attendue par nos patientes, l'avenir du dépistage du cancer du sein passera par une évaluation du risque sur base individuelle, permettant d'adapter, au mieux, l'âge de début ainsi que la fréquence et le type des examens utiles pour ce dépistage. Cet article passe en revue les trois grandes catégories de facteurs de plus haut risque disponibles pour établir un score de risque adapté à chaque patiente.

[Primary and secondary prevention for women at high risk for breast cancer]. / Prévention primaire et secondaire chez les femmes à haut risque de cancer mammaire.

Many factors determine a woman's risk of breast cancer; some genetic are related to family history, others are based on personal factors such reproductive and medical history. A high-risk woman must benefit of a specific screening regimen including breast examination, mammography, ultrasonography and contrast material-enhanced magnetic resonance. But she can also benefit of chemo prevention or/and risk-reducing surgery such bilateral prophylactic salpingo-oophorectomy and bilateral prophylactic mastectomy.

[Adherence to long-term medication: the particular case of the adjuvant endocrine therapy for breast cancer]. / L'observance au traitement de longue durée: le cas particulier de l'hormonothérapie adjuvante du cancer du sein.

The aim of adjuvant hormone therapy for breast cancer is to reach, in daily practice, an efficacy similar to that obtained in clinical trials. In spite of the demonstrated efficacy of hormone therapy, compliance represents a major challenge and a multidimensional problem. A better understanding of the reasons underlying non-compliance would help identify the patients at higher risk and would permit the implementation of strategies to improve compliance to adjuvant hormone therapy. With this in mind, we undertook a review of the recent literature on the topic (Pub Med 2003-2009).